Home Cart 0 Sign in  

[ CAS No. 380380-60-9 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 380380-60-9
Chemical Structure| 380380-60-9
Structure of 380380-60-9 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 380380-60-9 ]

Related Doc. of [ 380380-60-9 ]

Alternatived Products of [ 380380-60-9 ]

Product Details of [ 380380-60-9 ]

CAS No. :380380-60-9 MDL No. :MFCD08062726
Formula : C6H4BrN5 Boiling Point : -
Linear Structure Formula :- InChI Key :LBDJSOHAVRCQPD-UHFFFAOYSA-N
M.W : 226.03 Pubchem ID :23438683
Synonyms :

Calculated chemistry of [ 380380-60-9 ]

Physicochemical Properties

Num. heavy atoms : 12
Num. arom. heavy atoms : 11
Fraction Csp3 : 0.0
Num. rotatable bonds : 1
Num. H-bond acceptors : 4.0
Num. H-bond donors : 1.0
Molar Refractivity : 45.11
TPSA : 67.35 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : No
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -7.06 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.35
Log Po/w (XLOGP3) : 0.87
Log Po/w (WLOGP) : 1.02
Log Po/w (MLOGP) : 0.99
Log Po/w (SILICOS-IT) : 1.82
Consensus Log Po/w : 1.21

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.56

Water Solubility

Log S (ESOL) : -2.4
Solubility : 0.896 mg/ml ; 0.00396 mol/l
Class : Soluble
Log S (Ali) : -1.87
Solubility : 3.06 mg/ml ; 0.0135 mol/l
Class : Very soluble
Log S (SILICOS-IT) : -3.5
Solubility : 0.0723 mg/ml ; 0.00032 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 2.0

Safety of [ 380380-60-9 ]

Signal Word:Danger Class:4.1
Precautionary Statements:P240-P210-P241-P264-P280-P302+P352-P370+P378-P337+P313-P305+P351+P338-P362+P364-P332+P313 UN#:1325
Hazard Statements:H315-H319-H228 Packing Group:
GHS Pictogram:

Application In Synthesis of [ 380380-60-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 380380-60-9 ]
  • Downstream synthetic route of [ 380380-60-9 ]

[ 380380-60-9 ] Synthesis Path-Upstream   1~6

  • 1
  • [ 380380-60-9 ]
  • [ 50-00-0 ]
  • [ 380380-64-3 ]
YieldReaction ConditionsOperation in experiment
90.4% With 10% palladium on activated carbon; Degussa type; hydrogen In methanol at 20℃; for 3 h; 1.5 L of methanol,5-bromo-2- (2H-tetrazol-5-yl) pyridine (226 g)Formaldehyde (90g),10percent palladium on carbon (20 g) was added to the reactor,Under a hydrogen atmosphere (0.2 MPa)Stirred at room temperature for 3 hours, the reaction was completed,Organic phase evaporated,Recrystallization from acetonitrile,To give the product 2-methyl-5- (5-bromo-2-yl) tetrazolium,217 g, yield: 90.4percent.
Reference: [1] Patent: CN106632240, 2017, A, . Location in patent: Paragraph 0018-0019
  • 2
  • [ 380380-60-9 ]
  • [ 74-88-4 ]
  • [ 380380-64-3 ]
YieldReaction ConditionsOperation in experiment
70.5% With calcium hydroxide In dichloromethane; N,N-dimethyl-formamide at 0 - 40℃; for 24 h; The 5-bromo-2-(2H-tetrazol-5-yl)pyridine (20.0 g, 88.4 mmol) prepared in Example 1 was added with 20.0 mL of N,N-dimethyl formamide and 180.0 mL of methylene chloride and then further added with calcium hydroxide (3.94 g, 53.0 mmol), after which iodomethane (33.0 mL, 530.4 mmol) was slowly added dropwise thereto at 0°C. Thereafter, the reaction solution was warmed to 40°C and stuffed for 24 hr. After the termination of the reaction, the reaction solution was added with water, thus extracting an organic layer. The extracted organic layer was washed with saline and further extracted. The resulting organic layer was added with 300.0 mL of a 6 N hydrochloric acid aqueous solution to thus extract an aqueous layer, after which the separated organic layer was added with 60.0 mL of a 6 N hydrochloric acid aqueous solution, so that the aqueous layer was further extracted. Extraction was performed using HPLC until the amount of Ni was less than 5percent. The separated aqueous layer was collected, and the pH thereof was adjusted to 10.6 at 40°C or less using a 50percent sodium hydroxide aqueous solution. The produced solid was filtered, washed with water, and concentrated under reduced pressure, thus obtaining a desired compound. Yield (16.2 g, 70.5percent), N2/N] ratio percent (98/2)
Reference: [1] Patent: WO2017/99530, 2017, A1, . Location in patent: Paragraph 51; 52; 53; 54; 55; 56; 57
  • 3
  • [ 380380-60-9 ]
  • [ 74-88-4 ]
  • [ 380380-64-3 ]
  • [ 380380-63-2 ]
Reference: [1] European Journal of Organic Chemistry, 2016, vol. 2016, # 7, p. 1305 - 1313
[2] Patent: WO2004/48350, 2004, A2, . Location in patent: Page 60-61
[3] Patent: WO2004/56819, 2004, A1, . Location in patent: Page 52-53
[4] Patent: WO2004/56818, 2004, A1, . Location in patent: Page 52-53
[5] Patent: WO2004/56816, 2004, A1, . Location in patent: Page 52-53
[6] Patent: WO2008/108988, 2008, A1, . Location in patent: Page/Page column 52
  • 4
  • [ 74-88-4 ]
  • [ 380380-60-9 ]
  • [ 380380-64-3 ]
  • [ 380380-63-2 ]
YieldReaction ConditionsOperation in experiment
45% With sodium hydroxide In N,N-dimethyl-formamide at 0 - 20℃; Inert atmosphere To a solution of 2-(tetrazol-5-yl)-5-bromopyridine 8 (10.5 g, 46.5 mmol) in DMF (100 mL) at 0 °C was slowly added NaOH (6.50 g, 162 mmol) and iodomethane (4.08 mL, 65.5 mmol). After being stirred at room temperature for 6 h, the reaction mixture was poured into water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous MgSO4, filtered and concentrated in vacuo. The crude product was purified by column chromatography to obtain the title compound (5 g, 45percent). 1H NMR (CDCl3): δ 8.80 (d, J = 2.0 Hz, 1H), 8.13 (d, J = 8.4 Hz, 1H), 7.98 (dd, J = 8.4 Hz, 2.4 Hz, 1H), 4.42 (s, 3H).
4 g With sodium hydroxide In N,N-dimethyl-formamide at 0 - 20℃; for 6 h; Will be 10.5 grams2- (tetrazol-5-yl) -5-bromopyridine was dissolved100 ml of dimethylformamide,Then 6.5 g of sodium hydroxide was added to the solution,And 9.3 g of methyl iodide was slowly added to the solution at 0 ° C. The solution was stirred at room temperature for 6 hours,Water was then added and extracted with ethyl acetate.The resulting organic layer was washed with brine, dehydrated, filtered, concentrated in vacuo and purified by column chromatography to give 4 g of 2- (1-methyltetrazol-5-yl) -5-bromopyridine and 5 g of 2- (2 -methyltetrazol-5-yl) -5-bromopyridine.
Reference: [1] European Journal of Medicinal Chemistry, 2011, vol. 46, # 4, p. 1027 - 1039
[2] Bioorganic and Medicinal Chemistry, 2004, vol. 12, # 22, p. 5909 - 5915
[3] Patent: WO2005/58886, 2005, A1, . Location in patent: Page/Page column 26; 27
[4] Patent: WO2006/38100, 2006, A1, . Location in patent: Page/Page column 67-68
[5] Patent: CN106146559, 2016, A, . Location in patent: Paragraph 0050
[6] Patent: US2003/166620, 2003, A1,
[7] Patent: WO2005/116022, 2005, A1, . Location in patent: Page/Page column 50
[8] Patent: WO2005/116023, 2005, A1, . Location in patent: Page/Page column 67-68
  • 5
  • [ 18107-18-1 ]
  • [ 380380-60-9 ]
  • [ 380380-64-3 ]
  • [ 380380-63-2 ]
Reference: [1] Patent: US2004/33970, 2004, A1, . Location in patent: Page/Page column 9
  • 6
  • [ 380380-60-9 ]
  • [ 1056039-83-8 ]
Reference: [1] European Journal of Organic Chemistry, 2016, vol. 2016, # 7, p. 1305 - 1313
[2] Patent: WO2008/108988, 2008, A1,
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 380380-60-9 ]

Bromides

Chemical Structure| 380380-64-3

[ 380380-64-3 ]

5-Bromo-2-(2-methyl-2H-tetrazol-5-yl)pyridine

Similarity: 0.85

Chemical Structure| 380380-63-2

[ 380380-63-2 ]

5-Bromo-2-(1-methyl-1H-tetrazol-5-yl)pyridine

Similarity: 0.81

Chemical Structure| 211943-13-4

[ 211943-13-4 ]

3-Bromo-5-(1H-tetrazol-5-yl)pyridine

Similarity: 0.73

Related Parent Nucleus of
[ 380380-60-9 ]

Pyridines

Chemical Structure| 380380-64-3

[ 380380-64-3 ]

5-Bromo-2-(2-methyl-2H-tetrazol-5-yl)pyridine

Similarity: 0.85

Chemical Structure| 33893-89-9

[ 33893-89-9 ]

2-(1H-Tetrazol-5-yl)pyridine

Similarity: 0.84

Chemical Structure| 380380-63-2

[ 380380-63-2 ]

5-Bromo-2-(1-methyl-1H-tetrazol-5-yl)pyridine

Similarity: 0.81

Chemical Structure| 866117-17-1

[ 866117-17-1 ]

6-(1H-Tetrazol-5-yl)-2,2'-bipyridine

Similarity: 0.78

Chemical Structure| 211943-13-4

[ 211943-13-4 ]

3-Bromo-5-(1H-tetrazol-5-yl)pyridine

Similarity: 0.73